​

Zimmer Biomet (ZBH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ZBH Stock Forecast

Zimmer Biomet stock forecast is as follows: an average price target of $121.78 (represents a 13.95% upside from ZBH’s last price of $106.87) and a rating consensus of 'Hold', based on 20 wall street analysts offering a 1-year stock forecast.

ZBH Price Target

The average price target for Zimmer Biomet (ZBH) is $121.78 based on 1-year price targets from 20 Wall Street analysts in the past 3 months, with a price target range of $135.00 to $110.00. This represents a potential 13.95% upside from ZBH's last price of $106.87.

ZBH Analyst Ratings

Hold

According to 20 Wall Street analysts, Zimmer Biomet's rating consensus is 'Hold'. The analyst rating breakdown for ZBH stock is 0 'Strong Buy' (0.00%), 8 'Buy' (40.00%), 11 'Hold' (55.00%), 1 'Sell' (5.00%), and 0 'Strong Sell' (0.00%).

Zimmer Biomet Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 31, 2024Richard NewitterTruist Financial$117.00$106.929.43%9.48%
Oct 15, 2024Steven LichtmanOppenheimer$135.00$104.8328.78%26.32%
Oct 03, 2024Ryan ZimmermanBTIG$126.00$105.6919.22%17.90%
Oct 01, 2024Vijay KumarEvercore ISI$110.00$107.951.90%2.93%
Sep 13, 2024Richard NewitterTruist Financial$112.00$105.146.52%4.80%
Sep 10, 2024Caitlin CroninCanaccord Genuity$115.00$104.839.70%7.61%
Aug 08, 2024Jayson BedfordRaymond James$128.00$107.0919.53%19.77%
Aug 08, 2024Steven LichtmanOppenheimer$145.00$105.8137.04%35.68%
Aug 07, 2024Rick WiseStifel Nicolaus$130.00$107.5020.94%21.64%
Jul 15, 2024Drew RanieriMorgan Stanley$120.00$108.6910.41%12.29%
Jul 01, 2024Matt O'BrienPiper Sandler$115.00$108.535.96%7.61%
May 31, 2024Matthew O\'BrienPiper Sandler$140.00$114.4422.33%31.00%
May 30, 2024Shagun SinghRBC Capital$140.00$115.1421.59%31.00%
May 28, 2024Ryan ZimmermanBTIG$139.00$116.4119.41%30.06%
May 21, 2024David ToungArgus Research$150.00$119.0526.00%40.36%
Feb 06, 2023Truist Financial$137.00$128.466.65%28.19%
Feb 06, 2023Morgan Stanley$140.00$128.828.67%31.00%
Jan 09, 2023RBC Capital$141.00$125.7012.17%31.94%
Jan 06, 2023Morgan Stanley$135.00$126.776.49%26.32%
Dec 20, 2022Truist Financial$135.00$124.918.08%26.32%
Dec 12, 2022Citigroup$130.00$125.363.70%21.64%
Nov 23, 2022Larry BiegelsenWells Fargo$124.00$115.337.52%16.03%
Jul 18, 2022Stifel Nicolaus$120.00$104.6214.70%12.29%
May 04, 2022RBC Capital$128.00$122.204.75%19.77%
May 03, 2022Matt O'BrienPiper Sandler$130.00$121.377.11%21.64%
Mar 03, 2022Travis SteedBank of America Securities$120.00$122.13-1.74%12.29%
Feb 08, 2022Shagun Singh ChadhaRBC Capital$125.00$116.087.68%16.96%
Feb 08, 2022David TurkalyJMP Securities$145.00$116.0824.91%35.68%
Feb 08, 2022Samuel BrodovskyTruist Financial$128.00$116.0810.27%19.77%
Feb 07, 2022Jeff JohnsonRobert W. Baird$138.00$108.1327.62%29.13%
Feb 07, 2022Danielle AntalffyLeerink Partners$135.00$108.1324.85%26.32%
Feb 07, 2022Pito ChickeringDeutsche Bank$121.00$108.1311.90%13.22%
Feb 07, 2022Matthew O'BrienPiper Sandler$110.00$108.131.73%2.93%
Feb 07, 2022Michael MatsonNeedham$143.00$108.1332.25%33.81%
Feb 07, 2022Kyle RoseCanaccord Genuity$125.00$108.1315.60%16.96%
Jan 20, 2022Josh JenningsCowen & Co.$140.00$119.1417.51%31.00%
Dec 09, 2021Anders BylundMotley Fool$140.00$121.2315.48%31.00%
Nov 05, 2021Anthony PetroneJefferies$175.00$136.9027.83%63.75%
Nov 05, 2021Christopher PasqualeGuggenheim$180.00$136.9031.48%68.43%
Nov 04, 2021Vijay KumarEvercore ISI$170.00$133.1327.69%59.07%
Aug 04, 2021Steven LichtmanOppenheimer$190.00$143.0332.84%77.79%

The latest Zimmer Biomet stock forecast, released on Oct 31, 2024 by Richard Newitter from Truist Financial, set a price target of $117.00, which represents a 9.43% increase from the stock price at the time of the forecast ($106.92), and a 9.48% increase from ZBH last price ($106.87).

Zimmer Biomet Price Target by Period

1M3M12M
# Anlaysts-415
Avg Price Target-$122.00$128.13
Last Closing Price$106.87$106.87$106.87
Upside/Downside-100.00%14.16%19.89%

In the current month, the average price target of Zimmer Biomet stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Zimmer Biomet's last price of $106.87. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 15, 2024OppenheimerOutperformOutperformHold
Oct 14, 2024William BlairBuyBuyHold
Oct 03, 2024BTIGBuyBuyHold
Oct 01, 2024Evercore ISIPositivePositiveHold
Sep 17, 2024NeedhamHoldHoldHold
Sep 13, 2024Goldman SachsBuyBuyHold
Sep 13, 2024BarclaysUnderweightDowngrade
Sep 13, 2024Evercore ISIOutperformOutperformHold
Sep 13, 2024GuggenheimBuyBuyHold
Sep 10, 2024Canaccord GenuityHoldHoldHold
Sep 09, 2024Wolfe ResearchPeer PerformInitialise
Sep 05, 2024UBSEqual-WeightEqual-WeightHold
Sep 05, 2024Truist FinancialUnderperformUnderperformHold
Sep 05, 2024Cowen & Co.HoldHoldHold
Sep 05, 2024CitigroupNeutralNeutralHold
Aug 08, 2024OppenheimerOutperformOutperformHold
Jul 15, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Jul 10, 2024CitigroupNeutralNeutralHold
Jul 01, 2024Piper SandlerOverweightNeutralDowngrade
May 31, 2024Piper SandlerOverweightOverweightHold
May 30, 2024RBC CapitalOutperformOutperformHold
May 30, 2024CitigroupNeutralNeutralHold
May 30, 2024Goldman SachsNeutralInitialise
May 28, 2024Cowen & Co.HoldHoldHold
May 28, 2024BTIGBuyBuyHold
May 21, 2024Evercore ISIUnderperformUnderperformHold
May 21, 2024OppenheimerBuyBuyHold
May 03, 2024RBC CapitalUnderperformUnderperformHold
May 03, 2024Truist FinancialHoldHoldHold
Apr 03, 2024RBC CapitalHoldHoldHold
Apr 03, 2024CitigroupNeutralNeutralHold
Feb 09, 2024Raymond JamesUnderperformUnderperformHold
Feb 09, 2024RBC CapitalEqual-WeightEqual-WeightHold
Oct 17, 2023CFRAHoldUpgrade
May 03, 2023Bank of America SecuritiesNeutralUpgrade
May 03, 2023JMP SecuritiesOutperformOutperformHold
Apr 11, 2023Evercore ISIOutperformUpgrade
Mar 31, 2023JefferiesHoldUpgrade
Mar 09, 2023Piper SandlerNeutralOverweightUpgrade
Feb 06, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Feb 06, 2023OppenheimerOutperformOutperformHold
Jan 09, 2023RBC CapitalOutperformUpgrade
Jan 06, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Jan 05, 2023Piper SandlerNeutralNeutralHold
Jan 05, 2023Raymond JamesOutperformUpgrade
Dec 12, 2022CitigroupNeutralNeutralHold
Nov 23, 2022Wells FargoEqual-WeightUpgrade
Nov 03, 2022CitigroupNeutralNeutralHold
Aug 02, 2022Piper SandlerNeutralNeutralHold
Apr 26, 2022BTIGNeutralDowngrade
Feb 08, 2022NeedhamBuyBuyHold
Feb 07, 2022Canaccord GenuityHoldDowngrade

Zimmer Biomet's last stock rating was published by Oppenheimer on Oct 15, 2024. The company gave ZBH a "Outperform" rating, the same as its previous rate.

Zimmer Biomet Financial Forecast

Zimmer Biomet Revenue Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
Revenue----------------$183.70M$1.75B$1.87B$1.83B$1.83B$1.67B$1.78B$1.66B$2.04B$1.92B$2.03B$1.85B$2.09B$1.93B
Avg Forecast$2.30B$2.09B$2.21B$2.15B$2.20B$1.99B$2.12B$2.06B$2.11B$1.91B$2.03B$1.97B$2.01B$1.80B$1.94B$1.87B$1.93B$1.75B$1.83B$1.70B$1.76B$1.63B$1.72B$1.59B$2.07B$1.94B$1.97B$1.76B$2.08B$1.71B
High Forecast$2.35B$2.13B$2.25B$2.19B$2.24B$2.03B$2.16B$2.10B$2.15B$1.95B$2.06B$2.02B$2.03B$1.82B$1.94B$1.87B$1.97B$1.77B$1.86B$1.74B$1.79B$1.63B$1.72B$1.59B$2.07B$1.94B$1.97B$1.76B$2.08B$1.71B
Low Forecast$2.28B$2.07B$2.19B$2.13B$2.17B$1.97B$2.09B$2.04B$2.08B$1.89B$2.00B$1.94B$2.00B$1.78B$1.94B$1.87B$1.91B$1.73B$1.81B$1.68B$1.74B$1.63B$1.72B$1.59B$2.07B$1.94B$1.97B$1.76B$2.08B$1.71B
# Analysts5855107558541118991018211010139916101019131015
Surprise %----------------0.10%1.00%1.02%1.07%1.04%1.02%1.03%1.05%0.99%0.99%1.03%1.05%1.00%1.13%

Zimmer Biomet's average Quarter revenue forecast for Mar 24 based on 10 analysts is $1.87B, with a low forecast of $1.87B, and a high forecast of $1.87B. ZBH's average Quarter revenue forecast represents a 916.57% increase compared to the company's last Quarter revenue of $183.70M (Dec 23).

Zimmer Biomet EBITDA Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts5855107558541118991018211010139916101019131015
EBITDA----------------$183.70M$266.60M$329.60M$609.90M$454.40M$491.40M$525.50M$422.20M$420.20M$531.10M$556.40M$576.80M$549.90M$593.70M
Avg Forecast$632.52M$575.04M$607.53M$590.78M$603.46M$547.32M$580.91M$565.68M$578.69M$524.03M$556.13M$539.93M$553.04M$493.71M$532.63M$435.46M$529.45M$480.14M$501.47M$344.23M$195.80M$465.41M$490.39M$272.12M$588.63M$553.41M$562.27M$478.24M$592.63M$487.23M
High Forecast$644.58M$585.99M$619.10M$602.04M$614.96M$557.75M$591.98M$576.46M$589.72M$534.01M$566.72M$553.64M$558.54M$499.08M$532.63M$522.55M$539.54M$485.08M$511.03M$413.08M$234.96M$465.41M$490.39M$326.55M$588.63M$553.41M$562.27M$573.88M$592.63M$487.23M
Low Forecast$625.09M$568.27M$600.38M$583.83M$596.37M$540.88M$574.08M$559.03M$571.89M$517.86M$549.59M$531.71M$550.29M$488.35M$532.63M$348.36M$523.23M$474.76M$495.57M$275.39M$156.64M$465.41M$490.39M$217.70M$588.63M$553.41M$562.27M$382.59M$592.63M$487.23M
Surprise %----------------0.35%0.56%0.66%1.77%2.32%1.06%1.07%1.55%0.71%0.96%0.99%1.21%0.93%1.22%

10 analysts predict ZBH's average Quarter EBITDA for Mar 24 to be $435.46M, with a high of $522.55M and a low of $348.36M. This is 137.05% upper than Zimmer Biomet's previous annual EBITDA (Dec 23) of $183.70M.

Zimmer Biomet Net Income Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts5855107558541118991018211010139916101019131015
Net Income-----------------$162.80M$209.90M$232.50M$-130.20M$194.00M$153.70M$73.20M$-83.90M$145.60M$141.90M$198.10M$333.70M$242.50M
Avg Forecast$590.96M$481.12M$532.27M$508.49M$526.00M$429.94M$470.67M$450.02M$494.29M$391.87M$436.50M$415.56M$466.17M$354.02M$404.18M$19.50M$437.17M$324.36M$369.06M$15.42M$-92.87M$320.79M$338.71M$12.19M$395.66M$351.64M$372.18M$174.79M$413.03M$213.96M
High Forecast$605.60M$493.04M$545.45M$521.09M$539.03M$440.59M$482.32M$461.17M$506.53M$401.58M$447.31M$440.00M$474.28M$360.32M$404.18M$23.40M$444.04M$332.47M$378.20M$18.50M$-74.30M$320.79M$338.71M$14.62M$398.29M$351.64M$372.18M$209.75M$413.03M$213.96M
Low Forecast$581.93M$473.77M$524.13M$500.72M$517.96M$423.37M$463.47M$443.14M$486.73M$385.88M$429.83M$395.19M$458.06M$347.71M$404.18M$15.60M$430.31M$316.25M$363.41M$12.33M$-111.45M$320.79M$338.71M$9.75M$393.04M$351.64M$372.18M$139.84M$413.03M$213.96M
Surprise %-----------------0.50%0.57%15.08%1.40%0.60%0.45%6.01%-0.21%0.41%0.38%1.13%0.81%1.13%

Zimmer Biomet's average Quarter net income forecast for Dec 23 is $437.17M, with a range of $430.31M to $444.04M. ZBH's average Quarter net income forecast represents a 168.53% increase compared to the company's last Quarter net income of $162.80M (Sep 23).

Zimmer Biomet SG&A Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts5855107558541118991018211010139916101019131015
SG&A-----------------$674.90M$725.80M$715.90M$727.10M$654.90M$695.20M$684.50M$934.00M$802.40M$817.40M$770.10M$893.90M$790.00M
Avg Forecast$953.62M$866.95M$915.93M$890.69M$909.81M$825.16M$875.81M$852.85M$872.47M$790.05M$838.44M$814.03M$833.79M$744.35M$803.01M$939.98M$798.23M$723.88M$756.04M$743.07M$1.03B$675.47M$711.72M$587.41M$854.31M$803.20M$816.05M$679.50M$860.11M$707.14M
High Forecast$971.79M$883.47M$933.39M$907.66M$927.15M$840.88M$892.50M$869.10M$889.09M$805.10M$854.42M$834.69M$842.09M$752.43M$803.01M$1.13B$813.44M$731.33M$770.45M$891.69M$1.24B$675.47M$711.72M$704.89M$854.31M$803.20M$816.05M$815.40M$860.11M$707.14M
Low Forecast$942.41M$856.76M$905.16M$880.22M$899.11M$815.46M$865.51M$842.82M$862.21M$780.76M$828.59M$801.64M$829.64M$736.27M$803.01M$751.99M$788.84M$715.77M$747.15M$594.46M$826.11M$675.47M$711.72M$469.93M$854.31M$803.20M$816.05M$543.60M$860.11M$707.14M
Surprise %-----------------0.93%0.96%0.96%0.70%0.97%0.98%1.17%1.09%1.00%1.00%1.13%1.04%1.12%

Zimmer Biomet's average Quarter SG&A projection for Dec 23 is $798.23M, based on 18 Wall Street analysts, with a range of $788.84M to $813.44M. The forecast indicates a 18.27% rise compared to ZBH last annual SG&A of $674.90M (Sep 23).

Zimmer Biomet EPS Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts5855107558541118991018211010139916101019131015
EPS-----------------$0.78$1.01$1.11$-0.62$0.92$0.73$0.35$-0.40$0.70$0.68$0.95$1.61$1.17
Avg Forecast$2.91$2.37$2.62$2.50$2.59$2.12$2.32$2.22$2.43$1.93$2.15$2.05$2.30$1.74$1.99$1.87$2.15$1.60$1.82$1.64$1.83$1.55$1.64$1.40$1.92$1.70$1.80$1.48$2.00$1.04
High Forecast$2.98$2.43$2.69$2.57$2.66$2.17$2.38$2.27$2.50$1.98$2.20$2.17$2.34$1.77$1.99$1.87$2.19$1.64$1.86$1.68$1.89$1.55$1.64$1.42$1.93$1.70$1.80$1.48$2.00$1.04
Low Forecast$2.87$2.33$2.58$2.47$2.55$2.09$2.28$2.18$2.40$1.90$2.12$1.95$2.26$1.71$1.99$1.87$2.12$1.56$1.79$1.61$1.76$1.55$1.64$1.39$1.90$1.70$1.80$1.48$2.00$1.04
Surprise %-----------------0.49%0.56%0.68%-0.34%0.59%0.44%0.25%-0.21%0.41%0.38%0.64%0.80%1.13%

According to 18 Wall Street analysts, Zimmer Biomet's projected average Quarter EPS for Dec 23 is $2.15, with a low estimate of $2.12 and a high estimate of $2.19. This represents a 176.10% increase compared to ZBH previous annual EPS of $0.78 (Sep 23).

Zimmer Biomet Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
LUNGPulmonx$6.70$13.0094.03%Buy
CNMDCONMED$70.62$97.0037.35%Buy
OFIXOrthofix Medical$17.53$24.0036.91%
BRKRBruker$58.41$76.6731.26%Buy
BIOBio-Rad Laboratories$330.87$400.0020.89%Buy
MDTMedtronic$80.74$95.4018.16%Hold
ZBHZimmer Biomet$106.87$121.7813.95%Hold
ITGRInteger$134.76$153.5013.91%Buy
SYKStryker$367.11$413.1712.55%Buy
CVRXCVRx$13.17$14.258.20%Buy
ABTAbbott Laboratories$114.99$120.094.44%Buy
EWEdwards Lifesciences$75.65$76.330.90%Buy
SRDXSurmodics$39.44$39.500.15%Buy
GKOSGlaukos$151.16$148.86-1.52%Buy

ZBH Forecast FAQ

Is Zimmer Biomet a good buy?

No, according to 20 Wall Street analysts, Zimmer Biomet (ZBH) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 40.00% of ZBH's total ratings.

What is ZBH's price target?

Zimmer Biomet (ZBH) average price target is $121.78 with a range of $110 to $135, implying a 13.95% from its last price of $106.87. The data is based on 20 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Zimmer Biomet stock go up soon?

According to Wall Street analysts' prediction for ZBH stock, the company can go up by 13.95% (from the last price of $106.87 to the average price target of $121.78), up by 26.32% based on the highest stock price target, and up by 2.93% based on the lowest stock price target.

Can Zimmer Biomet stock reach $200?

ZBH's average twelve months analyst stock price target of $121.78 does not support the claim that Zimmer Biomet can reach $200 in the near future.

What are Zimmer Biomet's analysts' financial forecasts?

Zimmer Biomet's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $8.37B (high $8.53B, low $8.27B), average EBITDA is $2.3B (high $2.34B, low $2.27B), average net income is $1.88B (high $1.92B, low $1.85B), average SG&A $3.46B (high $3.53B, low $3.42B), and average EPS is $9.24 (high $9.47, low $9.1). ZBH's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $8.76B (high $8.93B, low $8.66B), average EBITDA is $2.41B (high $2.45B, low $2.38B), average net income is $2.11B (high $2.17B, low $2.08B), average SG&A $3.63B (high $3.7B, low $3.58B), and average EPS is $10.41 (high $10.67, low $10.25).

Did the ZBH's actual financial results beat the analysts' financial forecasts?

Based on Zimmer Biomet's last annual report (Dec 2023), the company's revenue was $1.94B, which missed the average analysts forecast of $7.21B by -73.08%. Apple's EBITDA was $1.26B, missing the average prediction of $1.86B by -32.28%. The company's net income was $0, missing the average estimation of $1.15B by -100.00%. Apple's SG&A was $0, missing the average forecast of $3.02B by -100.00%. Lastly, the company's EPS was $0, missing the average prediction of $7.21 by -100.00%. In terms of the last quarterly report (Dec 2023), Zimmer Biomet's revenue was $183.7M, missing the average analysts' forecast of $1.93B by -90.47%. The company's EBITDA was $183.7M, missing the average prediction of $529.45M by -65.30%. Zimmer Biomet's net income was $0, missing the average estimation of $437.17M by -100.00%. The company's SG&A was $0, missing the average forecast of $798.23M by -100.00%. Lastly, the company's EPS was $0, missing the average prediction of $2.15 by -100.00%